Obesity
Top in endocrinology: Incretin-based therapies; updated diabetes guidance
Incretin-based therapies, which were developed for the treatment of diabetes and obesity because of their ability to target defects that are not addressed by other medications, are continuing to evolve.
AGA opposes holding GLP-1 agonists for endoscopy without ‘high-level published evidence’
Updated AGA clinical practice guidelines reiterated the society’s stance that there is little data to support the recommendation that all patients should stop glucagon-like peptide-1 receptor agonists prior to elective endoscopy procedures.
Adults with obesity maintain weight loss at 88 weeks with continued tirzepatide therapy
Continued treatment with the GIP/GLP-1 dual agonist tirzepatide is necessary to maintain weight loss for adults with obesity, according to findings from the SURMOUNT-4 trial published in JAMA.
Targeting obesity may be ‘highly effective strategy’ for treating HFpEF, ASCVD
Findings from two cardiovascular outcome trials revealed that targeting obesity could become a major focus for treating cardiovascular disease and heart failure with preserved ejection fraction in the future, according to a speaker.
Providers must go beyond weight reduction when treating obesity
Adults with obesity can lose 15% or more of their body weight with nutrient-stimulated hormone-based therapies, but reducing body weight is not the only goal providers should have when treating obesity, according to a speaker.
Incretin-based medications transforming treatment of type 2 diabetes and obesity
The development of incretin-based molecules has led to therapies that can induce greater reductions in HbA1c and body weight for people with type 2 diabetes and obesity than other classes of medication, according to a speaker
Tobacco smoking attributed to more than 1 million cancer deaths in seven countries
Among four preventable risk factors for cancer mortality, smoking tobacco resulted in the most deaths and years of life lost in seven countries, according to data published in eClinicalMedicine.
Novel therapies targeting bile acid-triggered pathways may benefit children with NASH
Medications that target bile acid-triggered pathways and combination therapies could be the key for treating nonalcoholic steatohepatitis for young people with obesity and type 2 diabetes, according to a speaker.
Q&A: The advice PCPs should give to patients with overweight, obesity
As the first point of contact for many patients, it is important for primary care physicians to have strategies that will help treat and manage overweight and obesity, according to experts.
USPSTF recommends behavioral interventions for youth with high BMI
The U.S. Preventive Services Task Force has issued a draft recommendation encouraging physicians to provide or refer youth aged 6 years and older with a high BMI to intensive, comprehensive behavioral interventions.